Allstripes announces collaboration with taysha gene therapies for surf1-associated leigh syndrome program

San francisco--(business wire)--allstripes (formerly rdmd), a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced a multiyear collaboration with taysha gene therapies, inc. (nasdaq: tsha), a patient-centric gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. the collaboration will focus
TSHA Ratings Summary
TSHA Quant Ranking